Examines FDA’s repeated rejection of therapeutic treatments, raising questions about regulatory capture and agency accountability. Highlights concerns over centralized health authority’s impact on medical innovation and patient access to treatments.
FDA Rejects Outlook Therapeutics’ Eye Drug for Second Time in 2025
Examines FDA’s repeated rejection of therapeutic treatments, raising questions about regulatory capture and agency accountability. Highlights concerns over centralized health authority’s impact on medical innovation and patient access to treatments.…